secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-01-24T23:59:59+00:00
Accession:  0000950170-25-008603
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports updated Phase 1/2a data for [212Pb]VMT-α-NET: 3 objective responses, no DLTs
--------------------------------------------------------------------------------

- Three objective responses (1 confirmed, 2 unconfirmed) in Cohort 2 at 5.0 mCi dose; 5 stable disease; 1 progressive disease.
- No dose-limiting toxicities, grade 4/5 events, or SAEs reported; hematologic AEs were grade 1-2 only.
- Additional 11 patients dosed in Cohort 2 since August 2024, totaling 18 as of Dec 31, 2024.
- Company pursuing dose escalation to Cohort 3 after FDA consultation; data submitted to FDA in December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025008603/0000950170-25-008603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025008603/catx-20250124.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-008603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer